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Abstract 
High levels of psychotropic medication use and polyphar-
macy are common for emotionally and behaviorally trou-
bled youth entering residential care. Polypharmacy has 
often been characterized as an especially serious prob-
lem in this vulnerable population. Latent Class Analy-
sis was used to identify medication subgroups for 636 
youth in an intensive residential program. Addition-
ally, auxiliary analyses (e.g., diagnoses, demographics, 
expressed problem behaviors) were used to identify the 
personal and behavioral attributes associated with indi-
viduals in each of the latent classes. Three distinct med-
ication patterns emerged: low/no psychotropic medica-
tion, the combination of antidepressant and antipsychotic 
medications, and multiple psychotropic medications. The 
latent classes were significantly different from one an-
other on 12 of the 14 variables, helping explicate how 
patient and clinical characteristics underlie patterns of 
psychotropic medication use. Findings of this study, com-
bined with additional research, hold promise for leading 
to improved, youth-centered prescribing practices. Our 
findings also highlight the need for careful monitoring 
of the types and range of medications that some youth 
are prescribed, and research on how youth with certain 
background characteristics are more likely to get pre-
scribed multiple psychotropic medications. For youth ex-
periencing higher levels of psychotropic polypharmacy, 
medication regimens need thoughtful reassessment us-
ing the principle of sufficiency as the foundation for med-
ication management.
Keywords: Psychotropic medication, Polypharmacy, 
Residential care, Children and adolescents,  Latent 
Class Analysis
Introduction
For youth in need of emotional and behavioral inter-
vention, oftentimes there are high levels of psychotro-
pic medication use (Comer et al. 2010). For example, 
the use of off-label (i.e., prescribing a drug for a condi-
tion other than that for which it has been officially ap-
proved) atypical antipsychotic medications has increased 
over the last 10 years (Harrison et al. 2012; Olfson et al. 
2010; Rubin et al. 2012). A review of relevant literature 
found that polypharmacy (i.e., treatment using two or 
more psychotropic medications) increased 5.1 fold, from 
4.8% to 24.7% for youth on a stimulant between 1996 
and 2002 (Safer et al. 2003). An examination of Medic-
aid claims found a 6.2 fold increase in polypharmacy from 
6.7% to 41.6% for depressed adolescents between 1996 
and 2005 (McIntyre and Jerrell 2009). Similarly, between 
1996 and 2007, the polypharmacy rate increased from 
14% to 20% for youth prescribed psychotropic medica-
tion by an office-based physician (Comer et al. 2010), and 
has been reported to be as high as 60% for youth seeing 
an office-based psychiatrist (Mojtabai and Olfson 2010). 
An additional challenge in this area is that youth expe-
riencing polypharmacy tend to be on medications from 
multiple psychotropic medication categories (e.g., mood 
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stabilizers and antipsychotics) and even prescribed mul-
tiple medications within any given category (Comer et al. 
2010; Spellman et al. 2010). The growing trend for youth 
to be on two or more medications far outpaces our ca-
pacity to evaluate and assess efficacy and safety (Saldaña 
et al. 2014; Tishler and Reiss 2012; Vitiello 2007). There 
is particular concern in relation to the adverse effects 
of psychotropic medications to the developing brain and 
body of children and adolescents (Correll and Carlson 
2006; Singh and Chang 2012).
Youth in out-of-home care settings are at much 
higher risk for polypharmacy, and it is especially prev-
alent in residential care settings where it is more the 
rule than the exception (Brüggemann et al. 2008). In-
deed, research examining youth in intensive, restrictive 
residential programs has found that between 78% and 
88% of youth were on a psychotropic medication at ad-
mission, with 57–67% being on two or more psychotro-
pic medications (Huefner et al. 2014; Lyons et al. 2004). 
Although elevated rates of polypharmacy use might be 
due to higher mental health needs, this practice none-
theless poses a much higher chance of potential health 
risks (Huefner et al. 2014; GAO 2011). Most psychotro-
pic medication research has focused on monopharmacy 
(i.e., treatment using a single medication), whereas rel-
atively little has examined polypharmacy (Taylor 2010; 
Vitiello 2005). While some polypharmacy combinations 
are supported by effectiveness trials, most are of un-
proven efficacy and may put patients at increased risk 
of drug interactions with uncertain gains in terms of 
quality of care or improved clinical outcomes (Mojtabai 
and Olfson 2010). For example, although it has been ob-
served that the use of combined medications for youth 
with comorbid disorders or complex symptom presen-
tation may be clinically justified and effective in certain 
instances (Gadow et al. 2016; Linton et al. 2013; Pappa-
dopulos et al. 2003; Wilens 2009), these studies are al-
most exclusively based on case reports and small-scale, 
non-blind assessments (Safer et al. 2003).
More often than not, however, the psychotropic poly-
pharmacy pattern for youth does not match a research-
supported combination. For example, Pruitt and Kiser 
(2004) found the most frequently occurring multi-psy-
chotropic combinations for children with serious emo-
tional disturbance receiving treatment at a university 
school of medicine clinic were 1) mood stabilizer with 
an antidepressant or antipsychotic (9.4%), 2) antide-
pressant with a stimulant (9.4%), 3) stimulant with an 
alpha agonist (7%), and 4) mood stabilizer, antidepres-
sant, antipsychotic, and alpha agonist (5%). The com-
plexity of polypharmacy patterns following current prac-
tice for troubled youth presents a tremendous challenge 
to practitioners and researchers. Beyond the work of 
Pruitt and Kiser (2004), we do not yet know the com-
mon patterns, especially for those youth most likely to 
be on psychotropic medications (e.g., highly troubled 
emotionally and behaviorally disordered youth like those 
found in residential care settings). Additionally, because 
of exclusionary criteria utilized in randomized clinical 
trials, there is limited empirical data on the treatment 
of youths with complex and comorbid conditions (Mar-
tin et al. 2003).
Most psychotropic medication research has exam-
ined individual medications, or even psychotropic medi-
cation subtypes (e.g., stimulants, antipsychotics, antide-
pressants) in isolation, whereas research has shown that 
in practice they frequently are used in a complex array of 
combinations. To tap into these complex combinations, 
Latent Class Analysis (LCA) can be utilized. LCA is a per-
son-centered analytic technique designed to identify sub-
groups of individuals with distinctive profiles/patterns 
(Jobe-Shields et al. 2015; Lanza et al. 2003). A key fea-
ture of LCA is that subgroup membership is not known 
and must be inferred from the data (Berlin et al. 2014). 
LCA has been used to identify underlying patterns of ille-
gal drug and alcohol use, as well as levels of disturbance 
within individuals with posttraumatic stress disorder 
(e.g., Green et al. 2010; Hedden et al. 2010; Patra et al. 
2009; Ramo et al. 2010). LCA has not, insofar as we can 
determine, been used to examine patterns of psychotro-
pic polypharmacy. The promise of this research is to pro-
duce findings with practical and empirical significance 
for understanding and classifying psychotropic medica-
tion use in children and adolescents.
Prior research examining psychotropic polypharmacy 
has used a wide range of variables in order to better un-
derstand and explain what increases the likelihood of 
polypharmacy in child and adolescent populations. For 
instance, research has shown that psychotropic polyphar-
macy has been related to sex, race, age, maltreatment, 
and out-of-home placement history. Specifically, poly-
pharmacy has been shown to be related to being male 
(Dean et al. 2006) and Caucasian (Raghavan and McMil-
len 2008), however the literature is inconsistent (e.g., 
Griffith et al. 2010; Logan et al. 2015). Polypharmacy is 
also related to being older at the time of admission (Dean 
et al. 2006), being younger at first out-of-home admis-
sion (Fite et al. 2008; Li et al. 2015), to having a history of 
maltreatment (Fontanella et al. 2009; Schilling and Chris-
tian 2014), and having experienced a greater number of 
out-of-home placements (Saldaña et al. 2014; Stambaugh 
et al. 2012). Additionally, researchers have also found that 
polypharmacy is related to clinical factors, such as diag-
nosis and current behavior problems (Logan et al. 2015; 
Raghavan and McMillen 2008). However, no research to 
date has examined these variables in relation to distinct 
patterns of polypharmacy reflecting specific combinations 
of medication use found among youth in a residential care 
setting. To address this gap, these variables will be used 
as predictors of medication classes identified via LCA.
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This study represents an initial and unique attempt 
at identifying and describing naturally occurring groups 
of psychotropic medication usage among youth entering 
residential care, and if youth characteristics such as age, 
out-of-home placement history, diagnosis, and level of 
disruptive behavior are related to those patterns.
Method
Participants
The sample for this study included all youth who were 
admitted for the first time to an intensive residential pro-
gram in the Midwest (US) between January 2008 and Oc-
tober 2014 (n = 636). The treatment model for this psy-
chiatric residential treatment facility (PRTF) is based on 
a modified teaching-family model (Daly and Davis 2003; 
Daly et al. 1998). Requirements for admission into this 
program include having failed at other less restrictive 
placement settings, having at least one Axis I diagnosis, 
and having an IQ above 80. Comorbidity rates are fairly 
high in this population, with 68% of the youth having 
two or more classes of diagnosis (e.g., a behavioral dis-
order and a mood disorder). Of these youth, 340 (53.5%) 
were wards of the state and 271 (42.6%) had their stay 
funded by Medicaid. The overall sample means or per-
centages for the predictor variables used in the analysis 
are shown in Table 1.
Procedure
All data used in the study came from the organization’s 
administrative database. Admission data were collected 
by admission counselors prior to entry to the program, 
medication data were collected by nursing staff at the 
time of admission, and initial problem behavior was col-
lected by direct-care staff during the first two weeks in 
the program. The research protocols were reviewed and 
approved by the organization’s internal review board 
(IRB) according to federal guidelines.
Measures
Demographics
Demographic variables extracted from the administrative 
database include: (a) gender, (b) age at admission, (c) 
number of prior placements, (d) age at first placement, 
(e) race (recoded to Caucasian/minority), and (f) whether 
youth had been sexually and/or physically abused (based 
upon history provided by the referral source).
Clinical Diagnosis
A comprehensive psychological assessment prior to ad-
mission was available for most youth. This assessment 
was conducted by licensed clinicians in the community 
who are not affiliated with the residential treatment fa-
cility. The order in which the diagnoses are listed in the 
administrative data base does not indicate primary vs. 
secondary diagnosis. The diagnoses listed for the youth 
were collapsed into three non-exclusive categories (i.e., 
youth could have one or more diagnoses): (1) behavior 
disorders, (2) mood disorders, and (3) other diagnoses 
(e.g., reactive attachment disorder).
Behavioral Incidents
Daily observations of significant youth behaviors come 
from direct observation of behaviors gathered in a clini-
cal management tool called the Treatment Progress Check-
list (TPC). The TPC is a modified version of Chamberlain’s 
Parent Daily Report (Chamberlain et al. 2006; Chamber-
lain and Reid 1987). The TPC report logs all significant 
events (e.g., property damage, self-destructive behavior, 
physical assault) that occur at the setting during each 
of the three shifts each day. Each recorded incident in-
cludes a descriptive narrative of the behavior or event, 
and staff categorize each incident using at least one of 46 
behavior codes. Each code has been operationalized so an-
swers are consistent across staff entries. Some incidents 
may include more than one code. Direct-care staff record 
these events in a TPC (paper form) at the end of each 
shift for each child (one form per day, divided into three 
Table 1. Sample means (SD) or percentages for the 14 predic-
tor measures
 M or %
Age at first placement 10.2 (4.7)
Age at admission 14.3 (2.5)
Prior placement number 3.6 (4.4)
Male 54.2%
Caucasian 63.1%
Initial problem behavior 
Aggression 14.7 
(29.9)
Oppositional 37.9 
(30.4)
Hyperactivity 16.5 (16.9)
Covert 4.8 (6.5)
Internalizing 9.1 (8.6)
Victim 28.3%
Admission diagnosis 
Behavior disorder 84.0%
Mood disorder 57.7%
Other disorders 49.4%
320 Huefner et al.  in Journal of Child and Family Studies  26 (2017) 
sections, one section for each shift). All staff working 
that shift (between 9 and 14 individuals) collaboratively 
complete the TPC form for each youth. For this study, 
behavioral incidents were grouped into 5 general areas: 
oppositional, hyperactive, aggressive, internalizing, and 
covert. Oppositional behavior is an aggregate of arguing, 
complaining, defiance, irritable mood, not participating 
in program, and swearing and/or obscenities. Hyperac-
tive behavior is an aggregate of fidgeting, homework in-
complete, interrupting often, off-task behavior, and talk-
ing excessively. Aggressive behavior is an aggregate of 
physical aggression, physical assault, physical assault 
attempt, property damage, and threatening. Internaliz-
ing behavior is an aggregate of crying, negative self-state-
ments, pouting, somatic complaints, and withdrawal. Co-
vert behavior is an aggregate of inappropriate boundaries, 
lying/cheating, secretive/suspicious behavior, stealing, 
and teasing/provoking.
Staff are extensively trained to use the TPC and the 
reliability of the daily observation of initial problem be-
havior in this population has been established previously. 
Research using this behavioral coding process has found 
an 83.5% interjudge agreement in regards to the “re-
portability” of youth behavior between direct-care staff 
responding to 43 scenarios (Wright 2001). Additionally, 
research examining the reliability of the coding pro-
cess within the population for this program found kappa 
coefficients between 0.66 and 0.97 for codes assigned for 
the same incident narratives (Larzelere 1996). Taken to-
gether, both at the level of reporting and coding, the be-
havioral coding process possesses adequate reliability.
The expression of problem behavior in youth often 
changes during the first few days in the PRTF. It fre-
quently starts low and then escalates as youth become 
more familiar with and test the boundaries of their new 
environment. Moreover, the behavioral intervention it-
self is designed to reduce youth’s problem behaviors, and 
significant reductions in the behaviors measured by the 
TPC occur over the first couple of months (Huefner and 
Vollmer 2014). We used the first two weeks of behavioral 
data in order to obtain stable data indicative behavioral 
problems at the time of admission that was relatively less 
impacted by suppression of the behavioral intervention.
Victimization
Victimization status was obtained from a form called the 
Presenting Problems Checklist (PPC), which is collected 
separately from all the other data used in this research. 
The PPC is used primarily by a separate division the or-
ganization, and is not systematically used by the PRTF 
for either clinical or administrative purposes (hence its 
use is sporadic). It is unlikely that completion of this 
form is based on any attribute of the youth entering the 
PRTF. The PPC is completed by admission staff based on 
information gleaned from the psychosocial history and 
other information collected in the admissions process, 
and contains a list of 50 problems (e.g., out of control of 
parental instruction, physically assaultive toward peers, 
school behavior problems, etc.). Three of the items (vic-
tim of neglect, victim of physical abuse, victim of sex-
ual abuse) were used to create a dummy variable—hav-
ing one or more of these items checked was scored as a 
“yes” for victimization. The program does not use a for-
mal measure of victimization, so there is no way to de-
termine victimization status for youth for whom a PPC 
was not completed.
Psychotropic Medications
All medications that the youth brought with them at the 
time of admission were recorded in the organization’s 
database by a psychiatric nurse as part of the admission 
process. Youth are sent to this residential program pri-
marily because they have behavioral issues (whether or 
not they have a formal behavioral disorder diagnosis). 
Many of their psychotropic medications at the time of 
admission are presumably aimed at helping them with 
their behavioral issues. From the information available 
to us, however, we cannot determine why youth were put 
on these medications, what other mediations have been 
tried, or even the extent to which the medications have 
impacted their behavior prior to entering the program. 
Complicating the matter, the psychotropic prescriptions 
for each youth were often made independently by a va-
riety of prescribers (psychiatrists, pediatricians, general 
practitioners). Taken together, youth’s complex treatment 
histories and multiple prescribers often result in medica-
tion patterns that are confusing to our psychiatrists and 
clinicians, as well as others (see Kingsbury et al. 2001; 
Rosenheck 2005).
For analysis, psychotropic medications were catego-
rized into one of six categories: (1) antianxiety, (2) an-
tidepressant, (3) antipsychotic, (4) mood stabilizer, (5) 
stimulant/NRI (norepinephrine reuptake inhibitor), or 
(6) alpha agonist. These categories are well established 
and widely used in psychotropic medication research 
(e.g., Jann et al. 2016; Olfson et al. 2009).
Data Analyses
LCA was used to identify subgroups of youth with unique 
profile of psychotropic medication use (Lanza et al. 
2003). The LCA was conducted with Mplus version 7.3 
(Muthén and Muthén 2012). In this study, the six med-
ication categories were modeled as dichotomous indi-
cators of a categorical latent variable representing sub-
group membership. A series of LCAs were conducted 
with increasing numbers of classes, with fit statistics 
and the substantive meaning of the solutions being used 
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to determine the number of classes. Fit indices included 
the Bayesian Information Criteria (BIC), the Vuong-Lo-
Mendell-Rubin Likelihood Ratio Test (VLMR-LRT), and 
the Bootstrapped Likelihood Ratio Test (BLRT). These in-
dices, along with the substantive meaning, were used to 
determine the best fitting solution (Berlin et al. 2014). 
The result with the smallest BIC is considered to be the 
best fitting. The VLMR-LRT and the BLRT compare a so-
lution with a specific number of classes to an answer 
with one less class. The null hypothesis for the VLMR-
LRT and BLRT is that a model with k classes and one with 
k−1 classes are not different from each other. A decision 
to reject the null hypothesis means that a solution with 
k classes provides a better fit to the data.
The 3-step approach advanced by Asparouhov and 
Muthén (2014a,b) was used to examine the relation be-
tween subgroup membership and several variables. The 
3-step approach was carried out in Mplus using the Aux-
iliary command (Muthén and Muthén 2012). The BCH 
(Block, Croon, & Hagenaars, 2004) option is used with 
the Auxiliary command to estimate mean-level differ-
ences between subgroup membership and continuous out-
come variables (i.e., age at admission to the current pro-
gram, prior number of out-of-home placements, and five 
classes of problem behavior [aggressive, oppositional, 
hyperactive, covert, and internalizing] expressed during 
the first two weeks of the current episode of care). Simi-
larly, the DCAT (distal categorical outcome) command is 
used with the Auxiliary command to examine the rela-
tion between subgroup membership and categorical out-
comes (i.e., biological sex, race, and history of victimiza-
tion [yes/no], and three classes of admission diagnosis 
[behavior disorder, mood disorder, and other disorder]). 
The BCH and DCAT are the preferred options for examin-
ing class membership differences across continuous and 
categorical outcomes, respectively, and have been shown 
to perform well (Asparouhov and Muthén (2014a,b).
Each of the auxiliary analyses for the 14 predictors 
is an independent statistical analysis, creating the need 
to control for alpha. We chose to use Holm’s step-down 
Bonferroni method to control for family-wise error rates 
(Holm 1979), with the family-wise error rate set at .05.
Complete data were available for 362 (56.9%) youth; 
12 of the 14 variables used in the present study had miss-
ing data. Three variables did not have any missing data 
(psychotropic medications, age at admission, and gen-
der), 11 variables had less than 2% of the sample missing 
(age at first placement, prior placement number, race, all 
5 behavioral indicators, and the three diagnostic catego-
ries). Only one variable, victimization status, had substan-
tial proportion of missing data at 43.1% missing. Missing 
data for this variable was due to administrative failure 
in inputting the data. The LCAs were based on complete 
data (psychotropic medications), while the auxiliary anal-
yses implemented list-wise deletion (the N for each anal-
ysis is shown in Table 3).
Results
Table 2 shows the fit statistics for three LCA models (2, 
3, and 4 class models) that were estimated. Examination 
of the fit statistics indicated that the 3-class model was 
the best fit for the data. The BIC, VLMR-LRT, and BLRT all 
indicated that the 3-class solution provided the best fit to 
the data. We also examined the substantive meaning of 
the 2, 3, and 4 class models. The 3-class solution seemed 
to provide the most conceptually meaningful solution. 
Entropy for the 3-class solution was acceptable (.70). The 
pattern for the three class solution across the medica-
tion categories is shown in Fig. 1. The three medication 
classes are (1) low/no psychotropic medications, (2) an-
tidepressant and antipsychotic medications, and (3) mul-
tiple psychotropic medications. Table 3 shows that there 
were significant differences between the 3 latent classes 
for 12 of the 14 predictor variables and lists the raw-score 
averages. These differences are discussed below.
Table 2. Fit statistics for one, two, three, and four class models
Number  Log  Number of free  
of classes likelihood parameters BIC VLMR-LRT BLRT    Entropy
1 −2037 6 4112.8 n/a n/a n/a
2 −1887 13 3857.9 293.6* 300.1* 0.87
3 −1852.7 20  3834.5  67.09*  68.6* 0.70
4 −1849.8 27 3873.8 5.71 5.8 0.76
The null hypothesis for the Vuong-Lo-Mendell-Rubin Likelihood Ratio Test (VLMR-LRT) and the Bootstrapped Likelihood Ratio Test (BLRT) 
is that models with k classes and one with k−1 classes are not different from each other. A decision to reject the null hypothesis means 
that a solution with k classes provides a better fit to the data. Underline indicates best fitting solution for a particular fit statistic.
* p < .001
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Medication Latent Classes
Low/No Psychotropic Medication Class
More than a quarter of the youth are represented by the 
low/ no psychotropic medications latent class (n = 176, 
28%). Most youth in this class were not on any psycho-
tropic medication at the time of admission, with lim-
ited numbers on an antidepressant, antipsychotic, or a 
stimulant/NRI.
The low/no psychotropic medications youth had the 
highest number of prior placements (M = 4.5), but this 
was not significantly higher than the antidepressant 
Fig. 1. Psychotropic medication 
patterns for the three class 
solution (class labels and 
percentage of sample shown) 
across the medication categories
Table 3. Univariate Chi-square scores testing for significant differences for the LCA classes across the 14 predictor 
measures
   Low/no   Anti-  Multiple  
   psychotropic  depressants/  psychotropic
   medications  anti-psychotics medications
   (n = 176)  (n = 179)  (n = 281)
 Overall χ2 N Mean S.E. Mean S.E. Mean S.E.
Age at first placement 35.20* 633 10.84a 0.39 12.05b 0.45 8.58a 0.32
Age at admission 73.34* 636 15.05a 0.17 15.59a 0.22 12.95b 0.21
Prior placement number 6.15 634 4.53 0.48 3.11 0.29 3.40 0.32
Male 27.24* 636 61.2%a 4.3 31.0%b 5.2 71.8%a 4.8
Caucasian 7.26* 624 55.1%a 4.0 71.0%b 5.5 65.4%ab 3.6
Initial problem behavior†      
Aggression 35.81* 636 7.26a 1.32 2.39b 2.10 27.06c 3.00
Oppositional 28.17* 636 36.55a 2.57 25.23b 2.63 46.85c 2.37
Hyperactivity 47.75* 636 14.34a 1.07 7.28b 1.45 23.75c 1.47
Covert 15.08* 636 4.70a 0.49 2.72b 0.50 6.15a 0.58
Internalizing 66.84* 636 5.22a 0.50 7.45b 0.80 12.43c 0.70
Victim‡ 12.16* 362 34.8%a 5.7 64.5%b 5.8 47.6%ab 4.4
Admission diagnosis     
Behavior disorder 21.09* 635 88.4%a .028 63.6%b .069 96.5%c .019
Mood disorder 66.02* 635 34.6%a .040 84.1%b .046 54.2%c .039
Other disorders 0.40 635 48.1% .041 47.9% .048 51.3% .035
† Problem behavior during the first 2 weeks of episode of care.
‡ Victim status only available for a random subset of youth; see Method section for specific details.
* Significant p < .05 correcting for family-wise error using Holm’s Bonferroni (Holm 1979).
The lettered superscripts following the class means indicate which means are statistically different; means that share a superscript letter 
are not significantly different.
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and antipsychotic medications youth. The initial levels 
of problem behavior for the low/no psychotropic med-
ications class was significantly lower than the multiple 
psychotropic medications youth and significantly higher 
than the antidepressant and antipsychotic medications 
youth for all three of these behavioral categories. Addi-
tionally, the low/no psychotropic medications youth were 
significantly higher than the antidepressant and antipsy-
chotic medications class for covert behaviors, and were 
significantly lower than the other classes for internaliz-
ing behavior (M = 5.2) problems. Low/no psychotropic 
medications youth also had the lowest levels of victim-
ization, but this was only significantly lower than the an-
tidepressant and antipsychotic medications youth. Con-
versely, the low/no psychotropic medications class had 
the highest percentage of minority youth (45%), but 
again this was only significantly different from the an-
tidepressant and antipsychotic medications class. The 
level of aggression for the low/no psychotropic medica-
tions youth was significantly higher than the antidepres-
sant and antipsychotic medications youth, but only about 
25% of the level of aggression of the multiple psychotro-
pic medications youth. While the levels for all types of 
problem behavior for this group were significantly lower 
than the multiple psychotropic medications class, they 
were equally likely to have a behavioral disorder diagno-
sis (94%) at the time of admission as the multiple psy-
chotropic medications youth. Conversely, low/no psycho-
tropic medications youth were the least likely to have 
a mood disorder diagnosis (24%) at admission. Low/
no psychotropic medications youth had a significantly 
higher percentage of males than the antidepressant and 
antipsychotic medications class.
Antidepressant/Antipsychotic Class
More than a quarter of the youth fell into the antidepres-
sant and antipsychotic medications latent class (n = 179; 
28%). Almost every youth in this class was on an antide-
pressant at the time of admission (98%), with 81% also 
being on an antipsychotic. Lower numbers of these youth 
were on a stimulant (28%), mood stabilizer (22%), and/
or antianxiety (13%) medication. Youth in this class were 
on an average of 2.9 psychotropic medications (SD = 1.1).
The antidepressant and antipsychotic medications 
youth had the oldest age at first out-of-home placement, 
which was significantly older than the low/no psycho-
tropic medications and multiple psychotropic medica-
tions youth. They also had the oldest average age of ad-
mission to the current program, which was significantly 
older than the multiple psychotropic medications class. 
The antidepressant and antipsychotic medications youth 
had the lowest number of prior placements, but this was 
not significantly lower than the other groups. These youth 
had the highest rate of victimization (65%), which was 
significantly higher than only the low/no psychotropic 
medications youth. Antidepressant and antipsychotic 
medications youth were significantly more likely than the 
other groups to be female (69%), and significantly more 
likely than the low/no psychotropic medications class to 
be Caucasian (71%). The antidepressant and antipsychotic 
medications youth had significantly lower levels of ag-
gression, oppositional, hyperactive, and covert problem 
behaviors during the first 2 weeks of program stay than 
either the low/no psychotropic medications or multiple 
psychotropic medications youth. This group’s level of in-
ternalizing problem behavior was significantly higher 
than the low/no psychotropic medications youth and 
significantly lower than the multiple psychotropic med-
ications youth. Antidepressant and antipsychotic medi-
cations youth were significantly less likely to have a be-
havioral disorder diagnosis and significantly more likely 
to have a mood disorder diagnosis than the other groups.
Multiple Psychotropic Medications Class
Just under half of the youth fit the multiple psychotropic 
medications class (n = 281; 44%). This group is charac-
terized by the highest percentages of youth on antipsy-
chotic (86%), mood stabilizer (60%), stimulant (50%), 
and alpha agonist (32%) medications. There were also 
multiple psychotropic medications youth on antidepres-
sant (40%) and antianxiety (2%) medications. Youth in 
this class were on an average of 3.2 psychotropic medi-
cations (SD = 1.6).
The multiple psychotropic medications youth had the 
youngest average age at first out-of-home placement, 
but were only significantly younger than the antidepres-
sant and antipsychotic medications youth. Multiple psy-
chotropic medications youth were also younger at the 
time of admission to the current program, significantly 
younger than the other two groups. The multiple psycho-
tropic medications class had the highest percentage of 
males (72%), but this was only significantly higher than 
the antidepressant and antipsychotic medications class. 
This group had significantly higher averages for aggres-
sion, oppositional, hyperactive, and internalizing prob-
lem behaviors than either of the other groups. They were 
significantly higher than the antidepressant and antipsy-
chotic medications class for covert behaviors. The multi-
ple psychotropic medications youth had the highest per-
centage of behavioral disorder diagnoses (98%), but this 
was only significantly higher than the antidepressant and 
antipsychotic medications class. Multiple psychotropic 
medications youths’ level of mood disorder diagnosis was 
significantly lower than that for the antidepressant and 
antipsychotic medications youth, but significantly higher 
than that for the low/no psychotropic medications youth.
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Discussion
We found that there are meaningful patterns in the pre-
scribed psychotropic medications of youth who were ad-
mitted to an intensive psychiatric residential care pro-
gram. Three distinct medication patterns emerged: the 
low/ no medication latent class (most youth in this group 
were on no psychotropic medication at all with a few on 
antidepressants, antipsychotics, or stimulant/NRIs), the 
antidepressants/antipsychotic medication latent class 
(youth typified by almost all being on an antidepres-
sant, with significant numbers also being on an antipsy-
chotic, stimulant/NRI, mood stabilizer, and/or antianx-
iety), and the multiple psychotropic medication latent 
class (had the highest average number medication class 
prescriptions, with most youth on an antipsychotic, with 
the highest numbers on a mood stabilizer, stimulant/NRI, 
or alpha agonist). Additionally, the use of auxiliary vari-
ables allowed a better understanding of the attributes 
and characteristics of the individuals in each of the la-
tent groups.
The low/no psychotropic medications class accounted 
for about 28% of the youth. These were youth who 
tended to be older than the program average. This group 
also had the highest level of racial minority status (45%), 
which might indicate that these youth had less access to 
psychotropic medications. Previous research has found 
that even controlling for clinical acuity, African-Ameri-
can and Latino children were less likely to report past-
year psychotropic medication use compared to Cauca-
sian children (Leslie et al. 2003). There is a long history 
of research indicating that racial minorities appear to 
have unequal access to healthcare resources (Fossett et 
al. 1992; Raghavan et al. 2014), but this finding does 
not account for appropriateness of the medication (i.e., 
whether minorities might be under-medicated and/or 
Caucasians might be over-medicated). Previous research 
on the population examined in this study has found that 
there are overall reductions in the medication rates for 
youth (Huefner et al. 2014) and that there are not racial 
differences in outcomes (Ringle et al. 2012).
Conversely, low/no psychotropic medications youth 
had significantly lower levels of victimization (35%) than 
the antidepressant and antipsychotic medications class. 
However, this is just the percentage of youth with a re-
cord of physical or sexual abuse at some point, and does 
not indicate anything about the severity of that abuse. 
Perhaps a better approach would be to account for the 
extent (or count) of maltreatment (Felitti et al. 1998; Ip-
pen et al. 2011). Research has found that higher levels of 
trauma are associated with higher levels of psychotro-
pic medication (Anda et al. 2007; Brack et al. 2012). This 
may be another indication that youth in this class are not 
under-medicated. The antidepressant and antipsychotic 
medications class also accounted for about 28% of the 
youth. These youth were older in age at first-out-of-home 
placement, more likely to be female, and had the highest 
rate of victimization. These youth were also significantly 
more likely to have a mood disorder diagnosis, and al-
most all (98%) were admitted on an antidepressant. This 
group was least likely to have a behavioral disorder di-
agnosis (58%), which may be associated with the lower 
than average levels of aggressive, oppositional, hyperac-
tive, and covert behavior during the first two weeks of 
program stay. Interestingly, this group was not the high-
est for internalizing behavior problems during the first 
two weeks of stay in the program. Histories of victim-
ization and mood disorder are consistent with the use 
of antidepressants and antipsychotics (Brack et al. 2012; 
Burcu et al. 2014).
It is also notable that 81% in this group were also on 
an antipsychotic. The association of a mood disorder di-
agnosis with high levels of antipsychotics and antidepres-
sants is suggestive of anxious depression or severe mood 
dysregulation (Carlson et al. 2009; Leibenluft 2011). This 
pattern has also been associated with a bipolar diagno-
sis (Carlson et al. 2009; Findling et al. 2011), and self-
harm/suicidality (Brunner et al. 2014; Smith 2005). The 
antidepressant/antipsychotic combination aligns with an 
emerging effectiveness literature, and is suggestive of ad-
junct pharmacotherapy for treatment-resistive depres-
sion (e.g., anxious depression; Chena et al. 2011; Marcus 
et al. 2008; Papakostas 2010).
The multiple psychotropic medications class accounted 
for about 44% of the youth. Youth in this group had the 
highest average number of psychotropic medications 
(3.2) at the time of admission. Multiple psychotropic med-
ications youth had the youngest average age at first out-
of-home placement and the youngest average age at the 
time of admission to a psychiatric residential program. 
It is interesting that individuals in the multiple psycho-
tropic medications latent class tended to be placed into 
out-of-home services at younger ages, which may indi-
cate being more troubled and/or simply having had a lon-
ger period of time to accumulate more than one prescrip-
tion for psychiatric medication.
Almost all of these youth had a behavior disorder di-
agnosis, and half of them had a mood disorder diagno-
sis at the time of admission. This group differs from the 
antidepressant and antipsychotic group in terms of be-
haviorally acting out. The degree of disturbance in these 
youth is reflected in their high levels of behavioral act-
ing out during the first two weeks of their program stay. 
Multiple psychotropic medications youth expressed these 
higher rates of initial problem behavior in spite of enter-
ing the program on the highest average number of psy-
chotropic medications. Previous research has indicated 
that much initial problem behavior for youth in the pro-
gram studied here is aggressive in nature (Huefner et 
al. 2014). Aggressive behavior itself has been associated 
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with polypharmacy (Safer et al. 2003) and with dysreg-
ulated mood (Leibenluft 2011).
The pattern found in the multiple psychotropic med-
ications latent class was similar to research which sug-
gests that polypharmacy rates are highest for youth re-
ceiving antipsychotics (Dean et al. 2006). The high 
percentages of youth in this class concurrently on mood 
stabilizers, antipsychotics, and alpha agonists potentially 
is troubling as these all carry the potential for serious 
health-related side effects (Fontanella et al. 2009). The 
high rates of polypharmacy for this class may indicate a 
pattern where a high number of agents have been com-
bined in an attempt to find a medication or combina-
tion of medications that effectively improves a youth’s 
symptoms and behavior (Steiner and Karnik 2009). Some 
researchers have postulated that high pediatric poly-
pharmacy rates result from insufficient trials of mono-
pharmacy (e.g., inadequate dose, sufficient time frame, 
etc.), symptom-based prescribing, clinical encounter time 
constraints, managed care restrictions, and insufficient 
attention to psychosocial issues (Kingsbury et al. 2001; 
Rosenheck 2005).
Our results found that the multiple psychotropic med-
ications latent class, while having the highest rates of 
behavioral diagnoses, was not significantly higher than 
the behavioral diagnosis rate for the low/no psychotro-
pic medications class. However, it is very interesting to 
note that the multiple psychotropic medication class had 
significantly higher rates of initial problem behavior than 
either of the other medication classes (the exception be-
ing not significantly higher than the low/no psychotro-
pic medications class rate for covert behavior). The last 
factor, initial problem behavior, might be seen as provid-
ing clinical justification for the high medication rates, but 
conversely, one could argue that problem behavior rates 
should be suppressed by the elevated levels of concom-
itant/adjunctive medications (Griffith et al. 2010), al-
though problem behavior rates prior to medication ad-
ministration were unknown in this sample.
Our results do show that the latent groups found in the 
prescribed psychotropic medications at admission were 
related to interesting patterns of clinical need. Arguably, 
if severe mood dysregulation is accurate for the youth 
in the antidepressant and antipsychotic medications la-
tent class, then the pattern of psychotropic medications 
makes sense and is supported by research as an appropri-
ate treatment for these youth. Conversely, the medication 
patterns seen in the multiple psychotropic medications 
class do not conform to any supported clinical practice 
and is suspect by its apparent excess. On the other hand, 
given admission to an intensive residential program 
which serves youth with high levels of behavioral and 
emotional disturbance, there is the possibility that the 
low/no psychotropic medication latent class may be un-
der-medicated. In fact, that all these youth have been 
admitted to an intensive residential treatment program 
suggests that their medication regimens need thought-
ful reassessment using the principle of sufficiency as the 
foundation for medication management (i.e., using just 
enough medication as clinically indicated; Bellonci and 
Huefner 2014).
This study examined medication patterns at the time 
of admission to an intensive residential treatment cen-
ter, which is a helpful initial step in understanding the 
differing needs and challenges of youth with emotional 
and behavioral problems. Future research needs to look 
at how patterns of psychotropic medication use change 
over time for this population of youth. For example, what 
psychotropic medications are these youth on at the time 
of discharge, and do changes in medication correspond 
to changes in their diagnostic formulation? Additionally, 
are there differences in how youth in the different latent 
classes respond to the program intervention? Are youth 
in the low/no psychotropic medications class more likely 
to have a psychotropic medication added, and the multi-
ple psychotropic medications class to have psychotropic 
medications dropped? The adequacy of pharmacother-
apy to meet the clinical needs of these youth was not ad-
dressed in this study, and also needs to be addressed in 
future research. There is a need for longitudinal research 
that focuses on the relationship between placement his-
tory and psychotropic medication trials. Finally, there is 
a strong need for future research to examine the issue of 
medication dosage data in children and adolescents. What 
is the relationship between dosage and issues like treat-
ment effectiveness, practitioner conformity to practice 
guidelines, polypharmacy, and side effects?
One limitation of this study is the lack of standard-
ized measures of psychopathology. Such measures were 
only available for a limited number of the youth in the 
study. With the caveat that we only looked at broad di-
agnostic categories and level of troubled behavior dur-
ing the first two weeks in the program, the results re-
ported here emphasize the need to reassess children’s 
clinical and pharmacological therapeutic needs. A sec-
ond limitation is that the Auxiliary command in Mplus 
does not allow for the examination of multiple outcome 
variables simultaneously. As such, we are not able to in-
vestigate the three diagnostic dimensions together, and 
this limits the conclusions that we can make about the 
specificity of the relation between class membership and 
diagnosis. However, our analyses take a significant first 
step toward characterizing psychotropic medication use 
patterns among high-risk youth using LCA and provide 
a foundation on which future studies can build. Another 
limitation is that we only looked at youth admitted to 
one facility located in the Midwest. As it has been noted 
that there can be regional patterns of psychotropic med-
ication prescription (Aman et al. 2005; Radigan et al. 
2005; Rawal et al. 2004), it is possible that our results 
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reflect such a regional pattern. It should be noted, how-
ever, that the overall levels of psychotropic medication 
use found in these programs are consistent with those 
found in similar programs in other parts of the country 
(Breland-Noble et al. 2004; Connor et al. 1998; Ryan et 
al. 2008). Last of all, the PRTF does not use a system-
atic measure of victimization and the victimization data 
used in this research comes from a form that is inconsis-
tently completed by admissions staff. Both these issues 
create a very real limitation for the use of the victimiza-
tion data available to us, but we deemed victimization 
status sufficiently important to include it in the analysis.
Our results are an initial effort towards grouping and 
describing different classes of psychotropic medication 
usage among youth entering an intensive residential 
care program. Our findings highlight that many youth 
in residential care are on multiple psychotropic medi-
cations, and that there is a critical need to evaluate this 
practice. Our results also help explicate the patient and 
clinical characteristics that underlie the latent psycho-
tropic medication classes. These findings highlight the 
need for more careful monitoring of the types and range 
of medications that youth are prescribed. It is our be-
lief that this information, and that of further research 
examining the patterns of pediatric psychotropic medi-
cation use, will ultimately lead to improved, youth-cen-
tered prescribing practices.
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